Session 1: Setting the Scene – Neonatal and Rare Disease Drug Development

Back to: FDA ADEPT 10: Addressing Challenges in Neonatal Product Development

Presentations:

Neonates and Rare Diseases – Why Early Diagnosis and Approved Treatments are Imperative
Melissa Lestini, MD
OPT/OCMO/OC, FDA

Recognizing Common Challenges Across Investigations in Neonates and Rare Diseases Populations
Marshall Summar, MD
Uncommon Cures, Inc.